OCIL/CLEC2d Antibody (166C1309) - BSA Free

Western Blot: OCIL/CLEC2d Antibody (166C1309) [NB100-56553] - Analysis of OCIL in mouse spleen cell lysates. Thirty microgram of cell lysates per lane of mini gel.

• Reactivity: Mu
• Applications: WB
• Clone: 166C1309
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 0.5 mg/ml

OCIL/CLEC2d Antibody (166C1309) - BSA Free Summary

• Description: Novus Biologicals Mouse OCIL/CLEC2d Antibody (166C1309) - BSA Free (NB100-56553) is a monoclonal antibody validated for use in WB. Anti-OCIL/CLEC2d Antibody: Cited in 1 publication. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: This antibody was developed by immunizing mice with a synthetic peptide containing amino acids 2-18 (CVTKASLPMLSPTGSPQ) of mouse OCIL, GenBank no. gb|AAL37198.1.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: CLEC2D
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Western Blot 1-2 ug/ml
• Control:

  Mouse Spleen Whole Tissue Lysate (Adult Whole Normal)

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS containing 0.2% gelatin
• Preservative: 0.05% Sodium Azide
• Concentration: 0.5 mg/ml
• Purity: Protein G purified

Alternate Names for OCIL/CLEC2d Antibody (166C1309) - BSA Free

• CLAXLLT-1
• CLEC2D
• C-type lectin domain family 2 member D
• C-type lectin domain family 2, member D
• C-type lectin related f
• Lectin-like NK cell receptor
• Lectin-like transcript 1
• LLT1
• LLT1Osteoclast inhibitory lectin
• OCIL
• OCILmember D

Background

Recently, Zhou et al have identified a protein that can inhibit multinucleate Osteoclast formation in murine osteoblast and spleen cell co-cultures. This protein called, Osteoclast Inhibitory Lectin (OCIL) can also inhibit osteoclast formation in spleen cell cultures treated with RANKL and M-CSF. Furthermore, mOCIL acted directly on macrophage/monocyte cells as evidenced by its inhibitory action on adherent spleen cell cultures, which were depleted of stromal and lymphocytic cells. mOCIL completely inhibited osteoclast formation during the proliferative phase of osteoclast formation and resulted in 70% inhibition during the differentiation phase. Osteoblast OCIL mRNA expression was enhanced by parathyroid hormone, calcitriol, interleukin-1 and IL-11, and retinoic acid. OCIL is expressed in osteoblasts and chondrocytes as well as in a variety of extraskeletal tissues. Since OCIL expression was found to be very similar to distribution for RANKL, it has been suggested that RANKl and OCIL may interact in skeleton and in extracellular tissues.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for OCIL/CLEC2d Antibody (NB100-56553)(1)

Publication using NB100-56553

• Mathewson ND, Ashenberg O, Tirosh I et al Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis Cell 2021-02-16 [PMID: 33592174]
  
  Details:
  Citation using the Alexa Fluor 488 version of this antibody.

Bioinformatics

• Gene Symbol: CLEC2D
• Entrez:
  • 93694(Mouse)
• Uniprot:
  • AAK50881(Mouse)